Embed Size (px)
Citation preview
CV Date: January 13, 2014
Jiaoti Huang, M.D., Ph.D.
Professor of Pathology and Urology
Chief of Surgical Pathology
Director of Urologic Pathology
Departments of Pathology & Urology
David Geffen School of Medicine at UCLA
650 Charles E. Young Drive South, 13-229 CHS
Los Angeles, CA 90095-1732
Phone: 310-267-2264
E-mail: [email protected]
Education:
M.D. Anhui Medical University, Hefei, China, 09/78-08/83
M.S. Institute of Radiation Medicine, Beijing, China, 09/83-08/86
Ph.D. New York University School of Medicine, New York, NY, 09/87-08/91
Research Training:
1. Graduate Program, Institute of Radiation Medicine, Beijing, China, 09/83-08/86
2. Ph.D. Program, Molecular and Cellular Biology, New York University School of Medicine,
New York, NY, 09/87-08/91
3. Leukemia Society of America Postdoctoral Fellow, Department of Pharmacology, New York
University School of Medicine, New York, NY, 09/91-11/94
4. Leukemia Society of America Postdoctoral Fellow, Dept of Medicine, Yale University
School of Medicine, New Haven, CT, 12/94-06/95
Clinical Training:
Residency Anatomic and Clinical Pathology Residency Program, New York
University Medical Center, New York, NY, 07/95-06/99
Chief Residency Department of Pathology, New York University Medical Center, New
York, NY 07/98-06/99
Fellowship Oncologic Surgical Pathology Fellowship Program, Department of
Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY,
07/99-06/00
Academic Appointments:
1. Assistant Professor, Department of Pathology and Laboratory Medicine, University of
Rochester Medical Center, Rochester, NY, July 2000-Sept 2005
2. Associate Professor, Department of Pathology and Laboratory Medicine, University of
Rochester Medical Center, Rochester, NY, Oct 2005-2007
3. Associate Professor of Oncology, James P. Wilmot Cancer Center, University of
Rochester Medical Center, Rochester, NY, Oct 2006-2007
4. Associate Professor of Urology, Department of Urology, University of Rochester
Medical Center, Rochester, NY, Oct 2006-2007
5. Professor of Pathology, Urology and Oncology, University of Rochester Medical Center,
Rochester, NY, Feb 2008-Aug. 2008 6. Co-Director, Genitourinary Pathology Fellowship Program, Department of Pathology and
Laboratory Medicine, University of Rochester Medical Center, July 2002-Aug. 2008
7. Adjunct Professor, Department of Pathology and Laboratory Medicine, University of
Rochester Medical Center, Sept. 2008-2010
8. Professor and Director of Urologic Pathology, Department of Pathology and Laboratory
Medicine, UCLA David Geffen School of Medicine, Sept. 2008-present 9. Chief of Surgical Pathology, Department of Pathology and Laboratory Medicine, UCLA
David Geffen School of Medicine, June. 2013-present
10. Professor of Urology, UCLA David Geffen School of Medicine, Sept. 2009-present 11. Co-Director, Pathway Pathology Laboratory, UCLA Institute of Molecular Medicine
(IMED), June 2009-present
12. Member, Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, Oct
2009-present
13. Member, UCLA Jonsson Comprehensive Cancer Center, January 2010-present
Hospital Appointments:
1. Attending Pathologist, Strong Memorial Hospital, University of Rochester, July 2000-
2008
2. Director, Clinical Immunohistochemistry Laboratory, Department of Pathology and
Laboratory Medicine, University of Rochester Medical Center, July 2003-2008
3. Attending Pathologist, UCLA Ronald Reagan Medical Center, Sept. 2008-present
4. Director of Urologic Pathology, UCLA Ronald Reagan Medical Center, Sept. 2008-
present
5. Chief of Surgical Pathology, Department of Pathology and Laboratory Medicine, UCLA
David Geffen School of Medicine, June. 2013-present
Other Appointments:
1. Staff Scientist, Institute of Radiation Medicine, Beijing, China, 09/86-08/87
2. Consultant Pathologist, ImPath, Inc., New York, NY, 07/99-06/00
3. Member, Scientific Advisory Board, Egenix, Inc., 10/02-present
4. Chair, Scientific advisory Board, Egenix, Inc., 06/04-06/08
5. Deputy Chair, Scientific advisory Board, Egenix, Inc., 06/08-present
6. Visiting Professor, Anhui Medical University, China, August 2009-present
7. Visiting Professor, Peking University Wu Jieping Urologic Center, May 2011-present
8. Consultant, Verve Medical Inc., May 2012 – present
9. Consultant, Micatu Inc., July 2012 - present
Study Sections:
1. Study Section Member, Department of Defense Prostate Cancer Research Program, 2003.
2. Study Section Member, J&J Discovery Fund, University of Rochester, 2005, 2006
3. Scientific Reviewer, Roy J. Carver Charitable Trust, December 2006
4. Scientific Reviewer, Laboratory Support Center, Clinical and Translation Science
Institute (CTSI), University of Rochester, 2007
5. Study Section Member, SPORE applications in Prostate, Breast and Skin cancers,
National Cancer Institute, February 2007
6. Scientific Reviewer, Head and Neck SPORE supplement funds, National Cancer
Institute, May 2007
7. Study Section Member, Department of Defense Prostate Cancer Research Program, 2007
8. Study Section Member, Department of Defense Breast Cancer Research Program, 2008
9. Study Section Member, SPORE in Prostate, Ovarian, Pancreatic and Gastrointestinal
Cancers, National Cancer Institute, 2008
10. Scientific Reviewer, The Prostate Cancer Research Foundation, London, 2008
11. Study Section Member, SPORE in Skin and Prostate Cancers, National Cancer Institute,
2010
12. Study Section Member, Department of Defense Prostate Cancer Research Program, 2011
13. Review panel member, Fellowship Awards for Outstanding Students Studying Abroad,
Minister of Education of China, Dec 2011
14. Reviewer, the Williams Barker Bequest for research into cancer (2011/2012), the
Medical Research Foundation of the Medical Research Council (MRC), UK, January
2012
15. Online reviewer, Department of Defence Prostate Cancer Research Program (Detection,
Diagnosis and Prognosis), May 2012
16. Study section member, Cancer Group 4, National Natural Science Foundation of China,
July 2012
17. Study section member, Department of Defence Prostate Cancer Research Program,
Clinical and Experimental Therapeutics (CET-1) panel, October 2012
18. Member of the PCF Research Awards Standing Review Committee, 2013-present
19. Study section member, 2013 Department of Defence Prostate Cancer Research Program,
Pre-application-Clinical and Experimental Therapeutics-2, PRE-CET-2
20. Study section member, 2013 Department of Defence Prostate Cancer Research Program,
Exploration-Hypothesis Development-Clinical and Experimental Therapeutics-1 - Online
Reviewer
21. Study section member, 2013 Department of Defence Prostate Cancer Research Program,
Exploration-Hypothesis Development-Clinical and Experimental Therapeutics-2 - Online
Reviewer
22. Study section member, 2013 Department of Defence Prostate Cancer Research Program,
Clinical and Experimental Therapeutics-2, PRE-CET-2
Services in Professional Organizations:
1. Committee Member for Stipend Award, International Society of Urologic Pathology,
2008-2010
2. Cadre Leader for Genitourinary Pathology, The Cancer and Leukemia Group B (a
national clinical trial group sponsored by the National Cancer Institute), 2010-2011
3. Cadre Leader, Genitourinary Pathology, Alliance for Clinical Trials in Oncology, 2011-
present
4. Co-Chair, Prostate Cancer Foundation-China Initiative, Prostate Cancer Foundation,
October 2011-present
5. Judge, Excellence in GU Pathology Awards, United States & Canadian Academy of
Pathology and International Society of Urologic Pathology, 2013
Meetings Organized
1. First Annual Scientific Symposium of Prostate Cancer Foundation-China, March 2012,
Beijing, China
2. Second Annual Scientific Symposium of Prostate Cancer Foundation-China, May 2013,
Shanghai, China
Other Services:
1. Member, Residency Education Committee, UCLA Pathology and Laboratory Medicine,
2008-present
2. Expert Reviewer, China Ministry of Education Scholarship Committee, 2011-present
3. Member, Academic Personnel Committee, UCLA Pathology and Laboratory Medicine,
2011-2012
4. Chair, Academic Personnel Committee, UCLA Pathology and Laboratory Medicine,
2012-2013
5. Moderator, 2013 Amgen Scholars Program U.S. Symposium, July 20, 2013, Los Angeles,
CA
Areas of Clinical Expertise:
1. Genitourinary Pathology
2. Gynecological Pathology
3. General Surgical Pathology
4. Oncologic Surgical Pathology
5. Immunohistochemistry
Areas of Research Interests:
1. Neuroendocrine differentiation of prostate cancer and its role in disease progression
2. Novel biomarkers of prostate cancer
3. Novel therapeutics of prostate cancer targeting multiple signaling pathways
4. Improving imaging, biopsy and surgical planning for prostate cancer
Editorial Boards and Journal Reviewers:
1. Editorial Board Member, Prostate Cancer and Prostate Diseases, 08/01/12-present
2. Member, Overseas Editorial Board, Chinese Journal of Pathology, 07/02-present
3. Member, Overseas Editorial Board, Journal of Clinical and Experimental Pathology,
07/05-present
4. Editorial Board Member, Asian Journal of Andrology, 04/2007-present
5. Senior Editorial Board Member, American Journal of Translational Research, 2009-
present
6. Senior Editorial Board Member, American Journal of Cancer Research, 2010-present
7. Executive Editorial Board Member, International Journal of Clinical and Experimental
Pathology, 04/2007-present
8. Editorial Board Member, Analytic and Quantitative Cytology and Histology, 03/2007-
present
9. Editorial Board Member, The Open Prostate Cancer Journal, 09/08-present
10. Editorial Board Member, Chinese Journal of Urology, 09/10-present
11. Senior Editorial Board Member, Journal of Cancer Therapeutics and Research. 11/11-
present
12. Journal reviewer for: Cancer Research, Clinical Cancer Research, Prostate, Applied
Immunohistochemistry and Molecular Morphology, Asian Journal of Andrology,
American Journal of Pathology, Archives of Pathology and Laboratory Medicine,
Analytical and Quantitative Cytology and Histology, PloS Medicine, Human Pathology,
International Journal of Clinical and Experimental Pathology, British Journal of Cancer,
Endocrine-Related Cancer, Journal of Cellular and Molecular Medicine, Endocrinology,
Journal of Anatomy, Oncogene, Genes and Cancer, Prostate Cancer and Prostatic
Diseases, The Open Prostate Journal, BMC Urology, Journal of Thoracic Oncology, BMJ
Case Reports, Journal of Cancer Science and Therapy, International Journal of Cancer,
International Journal of Biologic Sciences, , Journal of Cancer Therapeutics and
Research, Cancer Biomarkers, Cell Cycle, Molecular Cancer Therapeutics, Cancer,
Biomed Central Genomics, International Journal of Urology, Journal of Urology, Cancer
Letters, PNAS
Professional Memberships:
1. United States and Canadian Academy of Pathology
2. American Association for Cancer Research
3. International Society of Genitourinary Pathology
4. Chinese American Pathologists Association
5. The Chinese Biological Investigators Society (life-time member)
Licensure: Full unrestricted medical license in the States of New York (License #: 211805)
and California (License #: 53385)
Board Certification: Diplomat of American Board of Pathology,
Combined Anatomic and Clinical Pathology, 2000
Honors and Awards:
1. China-US Biochemistry and Molecular Biology Examination Application (CUSBEA,
1987)
2. Leukemia Society of America Postdoctoral Fellowship ($75,000) (1992-1995)
3. Scientific Exchange Award, Leukemia Society of America ($5,000) (1993)
4. Eric A. Schenk Award for Excellence in Pathology Education, University of Rochester
Medical Center (Once a year, voted by pathology residents and fellows), 2006
5. Roberta Nieberg Faculty Teaching Award, UCLA Pathology and Laboratory Medicine
(Once a year, voted by pathology residents and fellows), 2008
6. Visiting Professor, Department of Urology, Massachusetts General Hospital of Harvard
University, June 2011
Grant Support
Finished grants:
1. Epigen Inc., “Expression of HCA protein in prostate cancer”.
Direct cost of $10,950 and 25% indirect cost (2002-2003)
Role: Principal Investigator
2. Epigen Inc., “Expression of HCA protein in metastatic prostate cancer”.
Direct cost of $20,000 and 25% indirect cost (2003-2005)
Role: Principal Investigator
3. R21 DK063126 “Inducible Gene Expression in Mouse Urothelium” (PI: Jay E. Reeder)
Agency: NIH
Period: Aug-01-2003 - Jul-01-2005
Award total: $315,000
%Effort: 5%
Role: co-Principal Investigator
4. Laboratory Support Fund “Targeting neuroendocrine cells of prostate cancer”
University of Rochester Clinical and Translation Science Institute
Role: PI
Period: 2008
Award total: $32,000
5. “RAD001 inhibition of neuroendocrine differentiation in prostate cancer”
Novatis Pharmaceuticals
Role: PI
Period: 2007-2008
Award total: $4,200
6 Translational Research Funds, UCLA Department of Pathology (PI: Clebanoff)
Period: 01/01/10 – 05/31/10
Title: Gene Profiling Studies to Identify molecular changes in pre-malignant prostate
tissue”
Award Total: $8,000
Role: Faculty Sponsor
7. Department of Defense Prostate Cancer Research Program PC061456 (PI: Huang)
Period: 1/1/2007 – 7/31/2010
Title: The Function of PTP1B in Neuroendocrine Differentiation of Prostate Cancer (PI:
Huang)
Award total: $351,000
Percent effort: 20%
Role: Principal Investigator
8 American Cancer Society RSG-07-092-01-TBE (PI: Huang)
Period: 1/1/2007 – 12/31/2010
Title: Neuroendocrine Differentiation and IL-8 Signaling in Prostate Cancer (PI: Huang)
Overall goals of the project: To study whether neuroendocrine differentiation and IL-8
signaling contribute to the progression of prostate cancer to the androgen-independent
state, using both cell culture models and human tissue.
Role: Principal Investigator
Direct cost: $200,000/yr
Percent effort: 40%
Role: Principal Investigator
9. Development Research Award from UCLA Prostate Cancer SPORE (PI: Huang)
Period: 2/1/2009-1/31/2011
Title: Targeting Neuroendocrine Cells of Prostate Cancer
Overall goals of the project: To study if the elimination of neuroendocrine cells in mouse
prostate cancer models may delay the development and progression of prostate cancer
Award total: $65,000
Role: Principal Investigator
10 UCLA Research Services Research Fund (PI: Huang)
Period: 5/1/2010 – 12/31/2010
Title: Gene Profiling Studies to Identify Molecular Changes in Basal, Luminal and
Stromal Cells of Pre-Cancerous Prostate Tissue
Overall goals of the project: To identify molecular alterations that represent early or pre-
cancerous stage in luminal, basal and stromal cells of the prostate
Award total: $20,000
Role: Principal Investigator
11 Postate Cancer Foundation Challenge Award (PI: Witte)
Period: 6/1/2008-5/30/2012
Title: Defining Targets and Biomarkers in Prostate Cancer Stem Cells: New Therapeutic
Opportunities
Direct cost: $750,000/yr
Role: Co-PI
12. Prostate Cancer Foundation Creativity Award (PI: Rettig)
Period: 5/1/2010-4/30/2012
Title: A Nano-Structured Platform for Enhanced Detection of CTCs in Prostate Cancer
Patients
Overall goals of the project: To detect and characterize circulating tumor cells in prostate
cancer patients for the purpose of prognosis and targeted therapy
Direct cost: $150,000/yr
Role: Co-PI
13. Cal-Tech-UCLA Joint Center for Translational Medicine Program (PI: Huang)
Period: 6/1/2011 – 5/31/2012
Title: Biomarkers for prostate cancer
Direct cost: $50,000
Role: Principal Investigator
14. Translational Research Funds, UCLA Department of Pathology (PI: Kerkoutian)
Period: 10/01/11 – 09/31/12
Title: Predicting the Aggressiveness of Prostate Cancer on Biopsy
Award Total: $20,000
Role: Faculty Sponsor
Current grants:
1 UCLA SPORE in Prostate Cancer (5P50CA092131-08) (PI: Robert Reiter)
Period: 1/7/2001 – 6/30/2018
Direct cost: $2,300,000/yr
Percentage effort: 20%
Role: Co-Director, Tissue Core
2. Department of Defense Prostate Cancer Research Program (Idea Development Award)
W81XWH-11-1-0227 (PI: Jiaoti Huang)
Period: 4/1/2011 – 3/31/2014
Title: The Function of Neuroendocrine Cells in Prostate Cancer
Direct cost: $150,000/yr
Percent effort: 10%
Role: Principal Investigator
3 NIH 1R01CA158627-01 (PI: Leonard Marks)
Period: 07/05/2011 – 06/30/2014
Title: Biopsy Tracking and MRI Fusion to Enhance Imaging of Cancer Within the
Prostate
Direct Cost: $487,849
Percent effort: 5%
Role: co-PI
4. Department of Defense Prostate Cancer Research Program W81XWH-12-1-0206 (PI:
Lily Wu)
Period: 07/01/2012 – 06/30/2015
Title: Disrupting the Pro-Tumorigenic Influences of Tumor-Infiltrating Myeloid Cells by
CSF1R Blockade to Augment Androgen Deprivation Therapy in Prostate Cancer
Direct cost: $150,000/yr
Percentage effort: 5%
Role: co-PI
5. Stand–up-to-Cancer Dream Team Award (PI: Eric Small and Owen Witte)
Period: 1/01/2013 -12/31/2015
Title: Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer
Direct Cost: $10,000,000 (all 3 years)
Percentage effort: 10%
Role: Pathologist
6. Prostate Cancer Foundation Honorable A. David Mazzone Special Challenge Award (PI:
Robert Reiter)
Period: 01/01/2013 – 12/31/2015
Title: Preventing Treatment Resistance by Co-Targeting Androgen Receptor and
SRC/MEK1-Dependent Epithelial to Mesenchymal Transition
Direct Cost: $2,000,000 (all 3 years)
Percent effort: 10%
Role: Co-PI and Pathologist
7. National Cancer Institute 1R01CA172603-01A1 (PI: Jiaoti Huang)
Period: 07/01/2013 – 6/30/2018
Title: A Novel Strategy to Identify Prostate Cancer Biomarkers for Patient Management
Direct cost: $1,037,500 (all 5 years)
Percent effort: 20%
Role: Principle Investigator
Publications:
1. Huang J. and Tang Z. Measurement of estrogen receptor in the nuclei of bone marrow cells
of male mice after the administration of estrogen. Bulletin Acad Mil Med Sci 1988; 2:24-26
2. Dolph PJ, Huang J, Schneider RJ. Translation by the adenovirus tripartite leader: elements
which determine independence from cap-binding protein complex. J Virol 1990; 64:2669-
77
3. Huang J, Schneider RJ. Adenovirus inhibition of cellular protein synthesis is prevented by
the drug 2-aminopurine. Proc Natl Acad Sci U S A 1990; 87:18 7115-9
4. Huang J, Schneider RJ. Adenovirus inhibition of cellular protein synthesis involves
inactivation of cap-binding protein. Cell 1991; 65:271-80
5. Levy JB, Canoll PD, Silvennoinen O, Barnea G, Morse B, Honegger AM, Huang J,
Cannizzaro LA, Park SH, Druck T, Huebner K, Barnea G, Sap J, and Schlessinger J. The
cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous
system. J Biol Chem 1993; 268:10573-81
6. Vogel W, Lammers R, Huang J, Ullrich A Activation of a phosphotyrosine phosphatase by
tyrosine phosphorylation. Science 1993; 259:1611-4
7. Sorokin A, Mohammadi M, Huang J, Schlessinger J. Internalization of fibroblast growth
factor receptor is inhibited by a point mutation at tyrosine 766. J Biol Chem 1994;
269:17056-61
8. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, Jaye M,
Crumley G, Schlessinger J, Lax I. Heparin-induced oligomerization of FGF molecules is
responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 1994;
79:1015-24
9. Huang J, Mohammadi M, Rodrigues GA, Schlessinger J. Reduced activation of RAF-1 and
MAP kinase by a fibroblast growth factor receptor mutant deficient in stimulation of
phosphatidylinositol hydrolysis. J Biol Chem 1995; 270:5065-72
10. Trachman JD, Huang J and Reem GH. Activation of human thymocytes induces the
phosphorylation of protein tyrosine phosphatase 1C. C. R. Acad Sci Paris de la vie/Life
Sciences 1995;318:367-74
11. Saric M, Applebaum RM, Culliford AT, Huang J, Scholes JV, Kronzon I. Massive Atrial
Septal Lipomatous Hypertrophy. Echocardiography 1999; 16: 833–834
12. Gu M, Shi W, Huang J, Barakat, RR, Thaler HT and Saigo PE. Association between initial
diagnostic procedure and hysteroscopy and abnormal peritoneal washings in patients with
endometrial carcinoma. Cancer (Cancer Cytopathology) 2000;90:143-7
13. Huang J, Behrens C, Wistuba I, Gazdar AF, Jagirdar J. Molecular analysis of synchronous
and metachronous tumors of the lung: Impact on management and prognosis. Ann Diagn
Pathol 2001;5:321-329
14. Huang J, Behrens C, Wistuba
II, Gazdar
AF, and Jagirdar, J. Clonality of combined tumors:
A molecular genetic study. Arch Pathol Lab Med 2002; 126: 437–441
15. Huang J and di Sant’Agnese PA. Neuroendocrine Differentiation in Prostate Cancer: An
Overview. in Advances in Oncology: The Expanding Role of Octreotide I. Page 243-262.
Ed. SWJ Lamberts and L Dogliotti. BioScientifica Ltd, Bristol, UK 2002
16. Liu Z, Huang J, Yan, Z and Tan, J: Application of flow cytometry in the diagnosis and
differential disgnosis of lymphoma and leukemia. Chinese J Path 2002; 31:352-353
17. Lee Y-F, Lin W-J, Huang J, Messing EM, Chan FL, Wilding G, and Chang C. Activation of
Mitogen-activated Protein Kinase Pathway by the Antiandrogen Hydroxyflutamide in
Androgen Receptor-negative Prostate Cancer Cells. Cancer Res 2002; 62:6039-6042
18. Ni J, Chen M, Zhang Y, Li R, Huang J and Yeh S. Vitamin E sccinate inhibits human
prostate cancer cell growth via modulating cell cycle regulatory machinery Biochem
Biophys Res Commun 2003; 300:357-63
19. Chen TS, McNully M, Hulbert W, di Sant’agnese and Huang J. Renal oncocytosis
presenting in childhood. A Case Report Intl J Surg Pathol 2003; 11:325-329
20. Daiss J, Carney J, Cartun R, Codington J, Erdrich C, Hinchman C, Huang J, Mauck J. and
Schnipelsky P. Human Carcinoma Antigen: A Marker Useful for Discriminating between
Benign Prostatic Hyperplasia and Prostate Cancer. J. Clinical Ligand Assay 2003; 26: 177-
180.
21. Li R, Yao JL, Bourne PA, di Sant’agnese PA and Huang J. Frequent expression of human
carcinoma-associated antigen (HCA), a mucin-type glycoprotein, by cells of prostatic
carcinoma. Arch Path Lab Med. 2004; 128: 1412-1417
22. Patton KT, Tretiakova MS, Yao JL, Papavero V, Huo L, Adley BP, Wu G, Huang J, Pins
MR, Teh BT and Yang XJ. Expression of RON proto-oncogene in renal oncocytoma and
chromophobe renal cell carcinoma. Amer. J. Surg. Pathol. 2004; 28:1045-50
23. Yao JL, Bourne PA, Yang Q, di Sant’Agnese PA and Huang J. Overexpression of Human
Carcinoma-Associated Antigen (HCA) in Urothelial Carcinoma of the Bladder. Arch Path
Lab Med. 2004;128:785–787
24. Hu Y-C, Yeh S-Y, Yeh S-D, Sampson EK, Li P, Hsu C-L, Ting H-J, Lin H-K, Wang L, Kim
Y, Huang J, and Chang C. Functional Domain and Motif Analyses of Androgen Receptor
Coregulator ARA70 and Its Differential Expression in Prostate Cancer. J Biol Chem 2004;
279:33438-46
25. Liang S, Yao JL, Bourne PA, di Sant’Agnese PA, Huang J and Lei J. Over-Expression of
Human Carcinoma-Associated Antigen in Esophageal Adenocarcinoma and its Precursor
Lesions. Amer J Clin Pathol 2004;122:747-51
26. Li R, Ni J, Yeh S, Bourne PA, Yao J, di Sant’agnese PA and Huang J. Cell culture block
array for immunocytochemical study of protein expression in cultured cells. Applied
Immunohistochemistry and Molecular Morphology 2005; 13:85-90
27. Huang J, Yao JL, Zhang L, Bourne PA, Quinn AM, di Sant’Agnese PA and Reeder JE.
Differential expression of Interleukin-8 and its receptors in the neuroendocrine and non-
neuroendocrine compartments of prostate cancer. Am J Pathol 2005; 166:1807-1815
28. Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, Huang J, Di Sant'Agnese PA, Lei JY.
Overexpression of Decoy receptor 3 in precancerous lesions and adenocarcinoma of the
esophagus. Amer J Clin Pathol 2005; 124:282-7 29. Sun Y, Gao D, Liu Y, Huang J, Lessnick S, Tanaka S. IGF2 is critical for tumorigenesis by
synovial sarcoma oncoprotein SYT-SSX1. Oncogene. 2006; 25:1042-52
30. Huang J, Wu C, Yao JL and di Sant’Agnese PA. Neuroendocrine differentiation in prostate
cancer. Proceedings of the 4th
Asian-Pacific International Academy of Pathology Congress.
Page 57-61. Ed. Wu BQ. Medimond S.r.l.. Bologna, Italy 2005
31. Huang J, Yao JL and di Sant’Agnese PA. Neuroendocrine Differentiation in Prostate
Cancer. In Prostate Cancer: Principles and Practice. Page 143-150. Ed Kirby R, Partin AW,
Feneley M, Parsons JK. Martin Dunitz Ltd (Taylor & Francis Group), London, UK 2005
32. Lei J., Bourne PA, di Sant’Agnese PA and Huang J. Cytoplasmic staining of TTF-1 in the
differential diagnosis of hepatocellular carcinoma versus cholangiocarcinoma and metastatic
carcinoma of the liver. Amer J. Clin Pathol 2006;125:519-525.
33. Wu C, Zhang L, Bourne PA, Reeder JE, di Sant’Agnese PA, Yao JL, Na Y and Huang J.
Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate
cancer. Prostate 2006; 66:1125-1135 .
34. Yao JL, Madeb R, Bourne PA, Lei J, Yang X, Tickoo, S, Liu Z, Tan D, Cheng L, Hatem F,
Huang J, and di Sant’Agnese PA. Small cell carcinoma of the prostate: an
immunohistochemical study. Am J Surg Pathol 2006; 30:705-12.
35. Huang J, Yao JL, di Sant’Agnese PA, Yang Q, Bourne PA, and Na Y.
Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate
2006; 66:1399-406.
36. Johnson A, Conover D, Huang J, Messing ME, Ning R, O'Connell M, Rossi M, Sun T, Wu
X and Reeder JE. Early Detection and Measurement of Urothelial Tumors in Mice. Urology
2006; 67:1309-14
37. Zhang Z, Rosen DG, Yao JL, Huang J, Liu J. Expression of p14(ARF), p15(INK4b),
p16(INK4a), and DCR2 increases during prostate cancer progression. Mod Pathol. 2006;
19:1339-43
38. Wu C, Yao
JL, di Sant’Agnese
PA, Na
Y, and Huang
J. Neuroendocrine differentiation in
prostate cancer. Chinese J Pathol 2006; 35 (9): 565-567
39. Wagner DG, Joseph J, Huang J and Xu H. Malakoplakia of the prostate on needle core
biopsy: A case report and review of the literature. Int. J. Surg. Pathol. 2006 15:86-9
40. Markhardt KB, Rubens DJ, Huang J and Dogra VS. Sonographic features of Biliary
Hamartomas with histopathological correlation. Journal of Ultrasound in Medicine 2006;
25:1631-3
41. Huang J, Wu C, di Sant’Agnese PA, Yao JL, Cheng L and Na Y. Function and molecular
mechanisms of neuroendocrine cells in prostate cancer. Anal Quanti Cytol Histol 2007; 29:
128-138 42. Wagner DG, Yao JL, di Sant’Agnese PA, Cheng L, Lopez-Beltran A, Montironi R and
Huang J. Soft tissue tumors in the prostate. Anal Quanti Cytol Histol 2007;29:341–350
43. Bhatt S, Huang J and Dogra VS. Littoral cell angioma of spleen: Radiologic-pathologic
correlation. Am J Roentgenology 2007;188(5):1365-6
44. Oh WK, Tay MH and Huang J. Is There A Role For Platinum Chemotherapy In
The Treatment Of Patients With Hormone-Refractory Prostate Cancer? Cancer 2007;
109(3):477-86
45. Liang JJ, Wang Z, Chiriboga L, Greco MA, Shapiro E, Huang H, Yang XJ, Huang J, Peng
Y, Melamed J, Garabedian M, Lee P. The expression and function of androgen receptor
coactivator p44 and protein arginine methyltransfersase 5 (PRMT5) in the developing testis
and testicular tumors. J. Urol. 2007; 177(5):1918-22
46. Wu C, and Huang J. PI3 kinase-AKT-mTOR pathway is involved in neuroendocrine
differentiation of prostate cancer. J. Biol. Chem. 2007; 282(6):3571-83
47. Wu C, Chen G, Na Y, Xin D, Yao JL, di Sant’Agnese PA and Huang J. The function of
Interleukin-8 in prostate cancer. In Progress in Chemokine Research. Eds Linkes WP.
Nova Science Publishers, Inc. New York, 2007. pp149-156.
48. Yao JL, Huang J and di Sant’Agnese PA. Small Cell Carcinoma of the Prostate. Diagnostic
Histopathology. 2008; 14/3: 117-121
49. Cheng L, Zhang S, Wang M, Davidson DD, Morton MJ, Huang J, Zheng S, Jones TD, Beck
SD, Foster RS: Molecular Genetic Evidence Supporting the Neoplastic Nature of Stromal
Cells in “Fibrosis” After Chemotherapy for Testicular Germ Cell Tumors. J Pathol 2007:
213: 65-71
50. Podder TK, Sherman J, Li L, Joseph J, Rubens DR, Messing EM, Huang J and Yu Y.
Mechanical properties of human prostate tissue in the context of surgical needle insertion.
Int. J. Computer Assisted Radiology and Surgery 2007; 2 (Suppl I):S106-S108
51. Ross RW, Beer
TM, Jacobus
S, Bubley
GJ, Taplin
M-E, Ryan
C, Huang J and Oh
WK for
the Prostate Cancer Clinical Trials Consortium (PCCTC). A Phase II study of carboplatin
plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory
to docetaxel. Cancer 2008; 112:521-6
52. Hui P, Wang HL, Chu P, Yang B, Huang J, Baergen RN, Sklar J, Yang XJ, Soslow RA.
Absence of Y chromosome in human placental site trophoblastic tumor. Mod Pathol. 2007;
20:1055-60 53. Li
L, Yao
JL, di Sant’Agnese PA, Bourne PA, Picken MM, Young AN, Shen SS
and Huang
J. Expression of Claudin-7 in Benign Kidney and Kidney Tumors. Intl. J. Clin. Exp.
Pathol. 2008; 1:57-64
54. Simon RA, di Sant’Agnese PA, Palapattu GS, Singer ea, Candelario gd, Huang J and Yao
JL. Mucinous Tubular and Spindle Cell Carcinoma of the Kidney with Sarcomatoid
Differentiation Intl. J. Clin. Exp. Pathol. 2008; 1:180-184
55. Johnson AM, O’Connell MJ, Miyamoto H, Huang J, Yao JL, Messing EM, Reeder
JE. Androgenic dependence of exophytic tumor growth in a transgenic mouse model of
bladder cancer: a role for thrombospondin-1. BMC Urology 2008; 8:7
56. Cheng L, Zhang S, Huang J and Na Y. A critical evaluation of the current classification
system for non-invasive papillary urothelial carcinoma. Chin. J. Urol. 2008; 29: 137-140
57. Li L, Xu H, Spalding BO, Cheng L, Simon R, Yao JL, di Sant’Agnese PA, Bourne PA and
Huang J. Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and
urothelial tumors. Hum Pathol 2008; 39:1205-11
58. Cai Y, Lee Y-F, Li G, Liu S, Bao B-Y, Huang J, Hsu CL and Chang C. A new prostate
cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. Int J.
Can. 2008; 123:195-201
59. Gobbo S, Eble JN, Huang J, Grignon DJ, Wang M, Martignoni G, Brunelli M, Cheng L:
Schwannoma of the kidney. Mod Pathol 2008; 21:779-83
60. Lei JL, Huang J. Cytoplasmic staining of TTF-1 in the differential diagnosis of
hepatocellular carcinoma. Expert Opinion on Medical Diagnostics 2008; 2:151-159
61. Liu B, Yu H-M I, Huang J, Hsu w. Co-opted Jnk/Sapk signaling in Wnt/b-catenin-induced
tumorigenesis. Neoplasia 2008; 10: 1004-1013
62. Deng X, Liu H, Huang J, Cheng L, Keller E, Parsons S and Hu C. Ionizing radiation induces
prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2:
Implications for disease progression. Cancer Research 2008;68:9663-70
63. Simon RA, di Sant'Agnese PA, Huang L-S, Xu H, Yao JL, Yang Q, Liang S, Liu, J, Lee R,
Cheng L, Oh WK, Palapattu G, Wei J, and Huang J. CD44 Expression is a Feature of
Prostatic Small Cell Carcinoma and Distinguishes it from its Mimickers. Hum Pathol
2009;40:252-8
64. Wagner DG and Huang J. Small Cell Carcinoma of the Prostate. eMedicine from WebMD.
Updated April 20, 2009. Available at: http://emedicine.medscape.com/article/1611899-
overview.
65. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang
L-S, Yang Q and Huang J. Selective expression of CD44, a putative prostate cancer stem
cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 2009
15;69:787-98
66. Sun Y, Niu J and Huang J. Neuroendocrine differentiation in prostate cancer. Am J Transl
Res 2009: 1:148-162
67. Huang J, Lee P, Mikami Y, Melamed J. Dysplastic ("in-situ") Lesions in multifocal renal
oncocytomas (oncocytosis). Int J Clin Exp Pathol. 2009;2:583-7.
68. Huang J and Witte ON. A Seminal Finding for Prostate Cancer? New Eng. J. Med. 2010;
362: 175-6
69. Yuan P, Kadara H, Behrens C, Tang XM, Woods D, Solis LM, Huang J, Spinola M, Dong
W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD
and Wistuba
II. Sex determining region Y-box 2 (SOX2) is a potential cell-lineage gene highly expressed
in the pathogenesis of squamous cell carcinomas of the lung. PLoS ONE. 2010; 5(2): e9112
70. Lawson DA, Zong Z, Memarzadeh S, Xin L, Huang J, Witte ON. Basal epithelial stem cells
are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A. 2010; 107:
2610-5
71. Shen P, Wei W, Yang X, Zeng H, Li X, Yang J, Wang J, Huang J. The influence of
percutaneous nephrolithotomy on human systemic stress response, SIRS and renal function.
Urol Res. 2010 Mar 4. [Epub ahead of print]
72. Marks LS and Huang J. Re: Copy number analysis indicates monoclonal origin of lethal
metastatic Prostate cancer. Words of Wisdom article. Eur. J. Urol. 2010; 57: 727-8
73. Silvers CR, Williams K, Salamone L, Huang J, Jordan CT, Zhou H, Palapattu GS A novel in
vitro assay of human prostate cancer tumor initiation. Prostate 2010; 70:1379-87
74. Brick A, Niu J, Huang
J and Oh WK. Possibility for Platinum Chemotherapy Treatment for
HRPC Patients? In Drug Management of Prostate Cancer. Eds Figg WD, Chau CH, Small
EJ. Chapter 14, pp 153-61. Humana Press, NJ, 2010
75. Ward SC, Huang J, Tickoo S, Thung SN, Ladanyi, M and Klimstra DS. Fibrolamellar
carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile
duct differentiation. Modern Pathol 2010 23:1180-90
76. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell-of-origin for
human prostate cancer. Science 2010;329:568-71.
77. Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin
SH, Mills GB, Liu J. CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell
Cycle, Diminished Apoptosis, and Enhanced Angiogenesis. Clin Cancer Res. 2010; 16:
3875-86
78. Fang F, Christian WV, Gorman SG, Cui M, Huang J, Tieu K, and Ballatori N. Neurosteroid
transport by the organic solute transporter OSTα-OSTβ. J Neurochemistry 2010;115:220-33
79. Memarzadeh S, Zong Y, Janzen DM, Goldstein AS, Cheng D, Kurita T, Schafenacker AM,
Huang J, Witte ON. Cell-autonomous activation of the PI3-kinase pathway initiates
endometrial cancer from adult uterine epithelium. Proc Natl Acad Sci U S A. 2010; 107:
17298-303
80. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Ladan F, Wada R,
Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, invasion,
metastasis and castration resistance. Nat Med 2010; 16:1414-20 PMID: 21057494
81. Kohli M, Williams K, Yao JL, Dennis RA, Huang J, Reeder J, Ricke WA. Thrombin
Expression in Prostate: A Novel Finding. Cancer Investigation. 2011; 29:62-67
82. Sun Y and Huang J. Novel genetic loci associated with prostate cancer in the Japanese
population. (Research Highlight Article) Asian J. Androl. 2010; 13:120-1
83. Wang J, Place RF, Huang V, Wang X, Noonan EJ, Magyar CE, Huang J and Li L-C.
Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated
overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer
Res 2010; 70:10182-91.
84. Cai H, Babic I, Wei X, Huang J and Witte ON. Invasive prostate carcinoma driven by c-Src
and androgen receptor synergy. Cancer Research 2011;71:862-72. PMID: 21135112
85. Goldstein AS, Drake JM, Burnes DL, Finley DS, Zhang H, Reiter RE, Huang J, and Witte
ON. Methods for the purification and direct transformation of epithelial progenitor cells from
primary human prostate. Nature Protocol. 2011; 6:656-67. PMID: 21527922
86. Williamson SR, Zhang S, Yao JL, Huang J, Lopez-Beltran A, Shen S, Osunkoya AO,
MacLennan GT, Montironi R, and Cheng L. ERG-TMPRSS2 Rearrangement is Shared by
Concurrent Prostatic Adenocarcinoma and Prostatic Small Cell Carcinoma and Absent in
Small Cell Carcinoma of the Urinary Bladder: Further Evidence Supporting Monoclonal
Origin. Mod Pathol, 2011 24:1120-7. PMID: 21499238
87. Wang S, Liu K, Liu J, Yu Z T-F, Xu X, Zhao L, Lee T, Lee EK, Reiss J, Lee Y-K, Chung
LWK, Huang J, Rettig M, Seligson D, Duraiswamy KN, Shen C K-F, Tseng H-R. Highly
Efficient Capture of Circulating Tumor Cells Using Nanostructured Silicon Substrates with
Integrated Chaotic Micromixers. Angew Chem Int Ed Engl. 2011; 50:2857 (PMID:
21381170)
88. Guo S, Sun F, Guo Z, Li W, Alfano A, Chen H, Magyar CE, Huang J, Chai TC, Qiu S, Qiu
Y. Tyrosine Kinase ETK/BMX Is Up-Regulated in Bladder Cancer and Predicts Poor
Prognosis in Patients with Cystectomy. PLoS One. 2011;6:e17778. PMID: 21408190
89. Cheng L, Zhang S, Alexander R, Yao Y, MacLennan GT, Pan CX, Huang J, Wang M,
Montironi R, Lopez-Beltran A: The landscape of EGFR pathways and personalized
management of nonsmall cell lung cancer. Future Oncology 2011; 7: 519-41. PMID:
21463141
90. Tai S, Sun Y, Squires JM, Zhang H, Oh K, Liang C-Z and Huang J. PC3 is a Cell Line
Characteristic of Prostatic Small Cell Carcinoma. Prostate. 2011; 71:1668-79 PMID:
21432867
91. Natarajan S, Marks LS, Margolis D, Huang J, Macairan ML, Lieu P and Fenster A. Clinical
application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol. 2011; 29: 334-42.
PMID: 21555104
92. Findeis-Hosey JJ, Huang J, Li F, Yang Q, McMahon LA and Xu H. High Grade
Neuroendocrine Carcinomas of the Lung Highly Express EZH2 but Carcinoids Do Not.
Hum Pathol 2011; 42:867-72. PMID: 21292308
93. Sun Y, Perera J, Rubin BP, Huang J. SYT-SSX1 (Synovial Sarcoma Translocated) regulates
PIASy to cause overexpression of NCOA3. J Biol Chem. 2011; 286:18623-32. PMID:
21454665
94. Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast
T, Wheeler TM, Srigley JR, Delahunt B, Egevad L; ISUP Prostate Cancer Group.
International Society of Urological Pathology (ISUP) Consensus Conference on Handling
and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling.
Mod Pathol. 2011; 24: 6-15. PMID: 20834234
95. van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, Montironi R,
Wheeler TM, Srigley JR, Egevad L, Delahunt B; ISUP Prostate Cancer Group. International
Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of
Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer
volume. Mod Pathol. 2011; 24: 16-25. PMID: 20818340
96. Magi-Galluzzi C, Evans AJ, Delahunt B, Epstein JI, Griffiths DF, van der Kwast TH,
Montironi R, Wheeler TM, Srigley JR, Egevad LL, Humphrey PA; ISUP Prostate Cancer
Group. International Society of Urological Pathology (ISUP) Consensus Conference on
Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic
extension, lymphovascular invasion and locally advanced disease. Mod Pathol. 2011; 24:26-
38. PMID: 20802467
97. Berney DM, Wheeler TM, Grignon DJ, Epstein JI, Griffiths DF, Humphrey PA, van der
Kwast T, Montironi R, Delahunt B, Egevad L, Srigley JR; ISUP Prostate Cancer Group
International Society of Urological Pathology (ISUP) Consensus Conference on Handling
and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and
lymph nodes. Mod Pathol. 2011; 24:39-47. PMID: 20818343
98. Tan PH, Cheng L, Srigley JR, Griffiths D, Humphrey PA, van der Kwast TH, Montironi R,
Wheeler TM, Delahunt B, Egevad L, Epstein JI; ISUP Prostate Cancer Group. International
Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of
Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol. 2011;
24: 48-57. PMID: 20729812
99. Cheng L, Zhang S, Huang J, Li N and Na Y. A critical evaluation of the current histological
grading system for non-invasive papillary urothelial carcinoma. Chin. J. Urol. 2011; 32:427-
431
100. Mulholland DJ, Tran LM Li Y, Cai H, Morim A, Wang W, Plaisier S, Garraway IP,
Huang J, Graeber TG, Wu H. Cell Autonomous Role of PTEN in Regulating Castration-
Resistant Prostate Cancer Growth. Cancer Cell. 2011; 19:792-804. PMID: 21620777
101. Memarzadeh S, Cai H, Janzen DM, Xin L, Lukacs R, Riedinger M, Zong Y, Degendt K,
Verhoeven G, Huang J, Witte ON. Role of autonomous androgen receptor signaling in
prostate cancer initiation is dichotomous and depends on the oncogenic signal. Proc Natl
Acad Sci U S A. 2011; 108:7962-7. PMID: 21518863
102. Goldstein AS and Huang J. Do neuroendocrine cells come up large in small cell lung
cancer? Cell Cycle. 2011;10:3627. PMID: 22024918
103. Tan N, Margolis DJA, McClure TD, Finley DS, Reiter RE, Huang J, Raman SS. Radical
prostatectomy: value of prostate MRI in surgical planning. Abdom Imaging, 2011; 37:664-
74. PMID: 2199356
104. Finley DS, Margolis D, Raman SS, Ellingson BM, Natarajan S, Tan N, Huang J, Reiter
RE. Fine-tuning robot-assisted radical prostatectomy planning with MRI. Urol Oncol. 2013;
31:766-75. PMID: 21906964
105. Huang L, Schauer IG, Zhang J, Mercado-Uribe I, Deavers MT, Huang J, Liu J. The
oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian
cancer. Int J Clin Exp Pathol. 2011;4:644-50. PMID: 22076164
106. Drake JM, Graham NA, Stoyanova T, Sedghi A, Goldstein AS, Cai H, Smith DA, Zhang
H, Komisopoulou E, Huang J, Graeber TG, Witte ON. Oncogene-specific activation of
tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A.
2012;109:1643-1648. PMID: 22307624
107. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, Gleave M, Wu H.
Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated
from prostate cancer stem/progenitor cells. Cancer Res. 2012; 72:1878-89. PMID: 22350410
108. Chen H, Sun Y, Wu C, Magyar E, Li X, Cheng6 L, Yao JL, Shen S, Osunkoya AO,
Liang C and Huang J. Pathogenesis of Prostatic Small Cell Carcinoma Involves the
Inactivation of the P53 Pathway. Endocr Relat Cancer. 2012;19:321-331. PMID: 22389383
109. Ding B, Sun Y, Huang J. Overexpression of SKI oncoprotein leads to P53 degradation
through regulation of MDM2 sumoylation. J Biol Chem. 2012;287:14621-30.PMID:
22411991
110. Tai S, Sun Y, Liu N, Ding B, Hsia E, Bhuta S, Thor RK, Damoiseaux R, Liang C and
Huang J. Combination of Rad001 (Everolimus) and Propachlor synergistically induces
apoptosis through enhanced autophagy in prostate cancer cells. Mol Cancer Ther. 2012;
11:1320-31; PMID: 22491797
111. Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, Calhoun-Davis T, Li H, Palapattu GS,
Pang S, Lin K, Huang J, Ivanov I, Li W, Suraneni MV, Tang DG. The PSA(-/lo) Prostate
Cancer Cell Population Harbors Self-Renewing Long-Term Tumor-Propagating Cells that
Resist Castration. Cell Stem Cell. 2012;10:556-69.
112. Liu N, Tai S, Ding B, Thor RK, Bhuta S, Sun Y and Huang J. Arsenic trioxide
synergizes with Everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through
increased autophagy and apoptosis Endocr Relat Cancer. 2012; 19:711-23. PMID:
22919067
113. Paik DY, Janzen DM, Schafenacker AM, Velasco VS, Shung MS, Cheng D, Huang J,
Witte ON, Memarzadeh S. Stem-Like Epithelial Cells are Concentrated in the Distal End of
the Fallopian Tube: A Site for Injury and Serous Cancer Initiation. Stem Cells. 2012;
30:2487-97. PMID: 22911892
114. Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J, Witte ON. Regulated
proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin
signaling. Genes Dev. 2012; 26:2271-85. PMID: 23070813
115. Sonn GA, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ, Marks
LS. Targeted Biopsy in the Detection of Prostate Cancer Using an Office Based Magnetic
Resonance Ultrasound Fusion Device. J Urol. 2012; 189:86-92. PMID: 23158413
116. Zong Y, Huang J, Sankarasharma D, Morikawa T, Fukayama M, Epstein JI, Chada KK,
Witte ON. Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via
paracrine Wnt signaling. Proc Natl Acad Sci U S A. 2012; 109:E3395-404. PMID:
23184966
117. Huang J, Wang JK, and Sun Y. Molecular Pathology of Prostate Cancer Revealed by
Next Generation Sequencing: Opportunities for Genome-Based Personalized Therapy. Curr
Opin Urol. 2013; 23:189-93. PMID: 23385974
118. Li Z, Chen CJ, Wang JK, Hsia E, Squires J, Sun Y and Huang J. Neuroendocrine
Differentiation of Prostate Cancer. Asian Journal of Andrology 2013; 15:328-32. PMID:
23503426
119. Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R6, Simons BW, Ward
JM , Robinson BD, Chu GC, Loda M, Thomas G, Borowsky A and Cardiff
RD. Animal
models of human prostate cancer: The Consensus Report of the New York Meeting of the
Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer
Research 2013; 73:2718-2736. PMID: 23610450
120. An J, Liu H, Magyar CE, Guo Y, Veena MS, Srivatsan ES, Huang J, Rettig MB.
Hyperactivated JNK Is a Therapeutic Target in pVHL-Deficient Renal Cell Carcinoma.
Cancer Res. 2013;73:1374-85 PMID: 23393199
121. Sonn GA, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ,
Reiter RE, Marks LS. Value of Targeted Prostate Biopsy Using Magnetic Resonance-
Ultrasound Fusion in Men with Prior Negative Biopsy and Elevated Prostate-specific
Antigen. Eur Urol. 2013 Mar 17. [Epub ahead of print] PMID: 23523537
122. Schelling LA, Williamson SR, Zhang S, Yao JL, Wang M, Huang J, Montironi R, Lopez-
Beltran A, Emerson RE, Idrees MT, Osunkoya AO, Man YG, MacLennan GT, Baldridge
LA, Compérat E, Cheng L: Frequent TMPRSS2-ERG rearrangement in prostatic small cell
carcinoma detected by fluorescence in situ hybridization: the superiority of FISH over ERG
immunohistochemistry. Hum Pathol 2013; 44:2227-2233.
123. Cheng L, Wang X, Teng, X, Huang J and Na Y. Recent development in the staging of
bladder urothelial carcinoma. Chin J. Urol. 2013; 34: 328-332
124. Seiler D, Zheng J, Liu G, Wang S, Yamashiro J, Reiter RE, Huang J, Zeng G.
Enrichment of putative prostate cancer stem cells after androgen deprivation: Upregulation of
pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell
lines. Prostate. 2013 Sep;73(13):1378-90. PMID: 23728788
125. Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, Wei M, Xu C, Wu C, Zhang Z, Gao X, Liu
Z, Hou J, Huang J, Sun Y. Long non-coding RNA metastasis associated in lung
adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for
diagnosing prostate cancer. Eur J Cancer. 2013; 49:2949-59. PMID: 23726266
126. Lu YT, Zhao L, Shen Q, Garcia MA, Wu D, Hou S, Song M, Xu X, Ouyang WH,
Ouyang WW, Lichterman J, Luo Z, Xuan X, Huang J, Chung LW, Rettig M, Tseng HR,
Shao C, Posadas EM. NanoVelcro Chip for CTC enumeration in prostate cancer patients.
Methods. 2013 Jun 28. doi:pii: S1046-2023(13)00220-X. 10.1016/j.ymeth.2013.06.019.
[Epub ahead of print] PMID: 23816790
127. Ren S, Liu Y, Xu W, Sun Y, Lu J, Wang F, Wei M, Shen J, Hou J, Gao X, Xu C, Huang
J, Zhao Y, Sun Y. Long Noncoding RNA MALAT-1 is a New Potential Therapeutic Target
for Castration-Resistant Prostate Cancer. J Urol. 2013 Jul 8. doi:pii: S0022-5347(13)04856-8.
10.1016/j.juro.2013.07.001. [Epub ahead of print] PMID: 23845456
128. Zong Y, Goldstein AS, Huang J. The molecular basis for ethnic variation and
histological subtype differences in prostate cancer. Sci China Life Sci. 2013; 56:780-7.
PMID: 23852643
129. Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H,
Montironi R, Tickoo SK, Zhou M, Argani P; ISUP Renal Tumor Panel. The International
Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J
Surg Pathol. 2013; 37:1469-89. PMID: 24025519
130. Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J,
Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR; Members of the ISUP
Renal Tumor Panel. The International Society of Urological Pathology (ISUP) grading
system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;
37:1505-17. PMID: 24025521
131. Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon
DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H; ISUP Renal Tumor Panel.
Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol. 2013; 37:1518-31.
PMID: 24025522
132. Chen R, Zeng X, Zhang R, Huang J, Kuang X, Yang J, Liu J, Tawfik O, Brantley
Thrasher J, Li B. Cav1.3 channel α1D protein is overexpressed and modulates androgen
receptor transactivation in prostate cancers. Urol Oncol. 2013 Sep 17. [Epub ahead of print]
PMID: 24054868
133. Gollapudi K, Galet C, Grogan T, Zhang H, Said JW, Huang J, Elashoff D, Freedland SJ,
Rettig M, Aronson WJ. Association between tumor-associated macrophage infiltration, high
grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer
Res. 2013; 3:523-9. PMID: 24224130
134. Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, Titz B, Huang J,
Pienta KJ, Graeber TG, Witte ON. Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier
CM, Sud S, Titz B, Huang J, Pienta KJ, Graeber TG, Witte ON. Proc Natl Acad Sci U S A.
110:E4762-9. PMID: 24248375
135. Stoyanova T, Cooper AR, Drake JM, Liu X, Armstrong AJ, Pienta KJ, Zhang H, Kohn
DB, Huang J, Witte ON, Goldstein AS. Prostate cancer originating in basal cells progresses
to adenocarcinoma propagated by luminal-like cells. Proc Natl Acad Sci U S A. 2013;
110:20111-6. PMID: 24282295
136. Sun F, Chen HG, Li W, Yang X, Wang X, Jiang R, Guo Z, Chen H, Huang J, Borowsky
AD, Qiu Y. Androgen receptor splice variant AR3 promotes prostate cancer via modulating
expression of autocrine/paracrine factors. J Biol Chem. 2013 Dec 2. [Epub ahead of print]
PMID: 24297183
137. Lusch A, Leary R, Heidari E, Liss MA, Okhunov Z, De Lorca AP, Huang J,
Wikenheiser J, Landman J. Intrarenal and Extrarenal Autonomic Nervous System Redefined.
J Urol. 2013 Dec 11. pii: S0022-5347(13)06085-0. doi: 10.1016/j.juro.2013.11.108. [Epub
ahead of print] PMID: 24333240
138. Chen Y, Nowak I, Huang J, Keng PC, Sun H, Xu H, Wei G, Lee SO. Erk/MAP Kinase
Signaling Pathway and Neuroendocrine Differentiation of Non-Small-Cell Lung Cancer. J
Thorac Oncol. 2014; 9:50-8. PMID: 24346093
139. Le JD, Huang J, and Marks LS. Targeted prostate biopsy: Value of multi-parametric
magnetic resonance imaging in detection of localized cancer. Asian Journal of Andrology
(in press)
140. Lipianskaya J, Cohen A, Chen CJ , Hsia E, Squires J, Li Z, Zhang Y, Li W, Chen X, Xu
H and Huang J. “Androgen-deprivation” therapy-induced aggressive prostate cancer with
neuroendocrine differentiation. Asian Journal of Andrology (in press)]
Invited Lectures and Presentations:
Invited by Academic Institutions:
1. Adenovirus inhibition of cellular protein synthesis is prevented by the drug 2-aminopurine.
Honors Program, Postgraduate School of New York University School of Medicine, 1990
2. Adenovirus inhibition of cellular protein synthesis involves inactivation of cap-binding
protein. Sacklar Institute of Biomolecular Medicine Research Seminar, New York University
School of Medicine, 1991
3. Adenovirus inhibition of cellular protein synthesis involves inactivation of cap-binding
protein. Special Seminar, Howard Hughes Medical Institute, University of California School
of Medicine at San Francisco, 1992
4. Adenovirus inhibition of cellular protein synthesis involves inactivation of cap-binding
protein. Howard Hughes Medical Institute, University of Washington at Seattle, 1992
5. Molecular pathology of lung cancer: Impact on prognosis and management. Grand Rounds,
Department of Pathology, New York University School of Medicine, May 1998
6. Molecular pathology of lung cancer: Impact on prognosis and management. Combined Grand
Rounds, Departments of Pathology, Cornell University School of Medicine and Memorial
Sloan-Kettering Cancer Center, November 4, 1999
7. Molecular pathology of lung cancer: Impact on prognosis and management. Department of
Pathology, Temple University School of Medicine, December, 1999
8. Immunohistochemistry in the diagnosis and differential diagnosis of poorly differentiated
tumors. Cancer Research Institute, Chinese Academy of Medicine, Beijing, China,
November, 2001
9. Immunohistochemistry in the diagnosis and differential diagnosis of poorly differentiated
tumors. Beijing University School of Medicine, Beijing, China, November, 2001
10. Immunohistochemistry in the diagnosis and differential diagnosis of poorly differentiated
tumors. Shanxi University School of Medicine, Taiyuan, China, November, 2001
11. Immunohistochemistry in the diagnosis and differential diagnosis of poorly differentiated
tumors. Dalian University School of Medicine, Dalian, China, November, 2001
12. Contemporary classification of renal tumors. Dalian University School of Medicine, Dalian,
China, November, 2001
13. Molecular Pathology of Lung Cancer. Department of Pathology, University of Chicago,
November, 2002
14. Pathology of prostate cancer. Chaoyang Hospital, Capitol Medical University, Beijing,
September 2003
15. Pathology of prostate cancer. The General Hospital of the Army, Beijing, September 2003
16. Neuroendocrine differentiation of prostate cancer. Roswell Park Cancer Center, July, 2004
17. Neuroendocrine differentiation of prostate cancer. Department of Urology, University of
Rochester Medical Center, July, 2005
18. Neuroendocrine differentiation of prostate cancer. Department of Pathology, University of
Rochester Medical Center, April, 2006
19. Neuroendocrine differentiation of prostate cancer. Department of Pathology, Emory
University School of Medicine, May, 2006
20. Grand Round Speaker, Department of Pathology, New York University School of Medicine,
March, 2007 (Neuroendocrine differentiation of prostate cancer).
21. Neuroendocrine differentiation of prostate cancer. Department of Pathology, School of
Medicine, University of California at Los Angeles, June 2007
22. Departmental Seminar Speaker, Department of Medicinal Chemistry and Molecular
Pharmacology, School of Pharmacy, Purdue University, September 2007 (Neuroendocrine
differentiation of prostate cancer).
23. Departmental Seminar Speaker, Department of Pharmacology & Experimental Therapeutics,
University of Maryland School of Medicine, June 2008 (Neuroendocrine cells in prostate
cancer).
24. Grand round speaker, Department of Pathology, University of Nebraska, Omaha, NE, May
2010 (Neuroendocrine cells in prostate cancer)
25. Grand round speaker, Brady Urology Institute, Johns Hopkins University Hospital, Baltimore,
MD, Dec 2010 (Neuroendocrine Differentiation in Prostate Cancer).
26. Neuroendocrine Differentiation in Prostate Cancer, UCLA Specialized Program of Research
Excellence (SPORE) in Prostate Cancer, April 2011
27. Pathology of Prostate Cancer, Wu Jie-Ping Urologic Center, Beijing University, May 2011
28. Neuroendocrine Differentiation in Prostate Cancer, Anhui Medical University, May 2011
29. Immunohistochemistry in the Differential Diagnosis of Genitourinary Tumors, Anhui
Medical University, May 2011
30. Neuroendocrine Differentiation in Prostate Cancer, Department of Urology, Massachusetts
General Hospital of Harvard University, June 2011
31. Immunohistochemistry in the Diagnosis and Differential Diagnosis of Genitourinary Tumors.
Adicon Clinical Laboratories Inc., Hangzhou, China, November 1, 2011
32. Medical Education in the United States, Anhui Medical University, Hefei, China. November
8, 2011
33. Medical-Legal Issues in the United States, the First Affiliated Hospital of Anhui medical
University, Hefei, China, November 10, 2011
34. Tissue recombination technology in cancer research, Cancer Center, Zhejiang University
School of Medicine, Hangzhou, July 2012
35. Neuroendocrine differentiation in prostate cancer, Department of Pathology, Yale University
School of Medicine, August 2012
36. Neuroendocrine Differentiation in Prostate Cancer, Department of Pathology, University of
California at Irvine, Irvine, CA, September 21, 2012
37. Neuroendocrine Differentiation in Prostate Cancer, Department of Urology, Tongji Hospital,
Huazhong University of Science and Technology, Wuhan, China, May 2013
38. Neuroendocrine Differentiation in Prostate Cancer, Department of Urology, West China
Hospital of Sichuan University, Chengdu, China, June 2013
39. Recent progress in prostate cancer. Soochou University Annual Translational Medicine
Meeting, Suzhou, China, November 2013
40. Recent progress in prostate cancer. Wuxi Second People's Hospital, Wuxi, China, November
2013
41. Recent progress in prostate cancer. National Center of Biomedical Analysis (NCBA),
Beijing, China, November 2013
Invited by Local, National and International Conferences
1. Adenovirus inhibition of cellular protein synthesis is prevented by the drug 2-aminopurine.
Cold Spring Harbor Meeting: Translational Control. 1989; Cold Spring Harbor, New York
2. Adenovirus inhibition of cellular protein synthesis involves inactivation of cap-binding
protein. American Society of Virology Annual Meeting, 1991; Fort Collings, Colorado
3. Molecular analysis of synchronous and metachronous tumors of the lung: Impact on
management and prognosis. XXI International Congress of the International Academy of
Pathology and 13th World Congress of Academic and Environmental Pathology, 1998; Nice,
France
4. Fibrolamellar carcinoma of the liver: Immunohistochemical study of 11 cases and
comparison with conventional hepatocellular carcinoma . 89th
Annual Meeting, United States
and Canada Academy of Pathology, New Orleans, LA, 2000
5. Prognostic significance of neuroendocrine phenotype expression in human prostate
carcinoma. International Symposium on Prostate Cancer: Novel Strategies for a New
Disease. Turin, Italy, September, 2003
6. Neuroendocrine differentiation of prostate cancer. The 4th Asia-Pacific IAP Congress,
August 23 – 26, 2005 Beijing, China
7. Plenary Speaker, 13th
Annual Meeting of the Chinese Urological Society, Shenyang, China,
October 2006 (Recent advances in the pathology of urological tumors).
8. Invited participant, 11th Prouts Neck Meeting on Prostate Cancer "Emerging Strategies in
Prostate Cancer Therapy", Prouts Neck, Maine, Nov 2-5, 2006
9. Plenary Speaker, Annual Meeting of the Chinese Society of Pathology, Chengdu, China,
April 2007 (Immunohistochemistry in the differential diagnosis of undifferentiated tumors)
10. Invited Speaker and Session Co-Chair, Nanjing International Symposium of New Frontiers in
Cancer Research, Nanjing, China, November 2007 (Neuroendocrine differentiation of
prostate cancer).
11. Plenary Speaker, 14th
Annual Meeting of the Chinese Urological Society, Xiamen, China,
November 2007 (Neuroendocrine differentiation of prostate cancer).
12. Plenary Speaker, 15th
Annual Meeting of the Chinese Urological Association, Kunming,
China, September 2008 (Neuroendocrine cells in prostate cancer).
13. Plenary Speaker, 11th Mid-east Association of the Urology of China, Huangshan, China,
June 2009
14. Invited Speaker, 16th
Annual Meeting of the Chinese Urological Association, Chengdu,
China, September 2009 (Recent advances in prostate cancer research).
15. The Function of Neuroendocrine Cells in Prostate Cancer. Prostate Cancer Foundation
Scientific Retreat. Reno, NV, Sept 2009
16. The Function of Neuroendocrine Cells in Prostate Cancer. NCI Translational Science
Meeting, Tyson Corer, VA. Nov 2009
17. Plenary speaker, 2010 Annual Scientific Meeting, the Association of Chinese American
Physicians, New York, NY, May 2010
18. Plenary Speaker, Anhui Province Pathologists Association Meeting, China, Oct 2010
(Pathologic Diagnosis of Bladder Cancer)
19. Plenary Speaker, Anhui Province Urologists Association Meeting, China, Oct 2010 (Recent
progress in prostate cancer and new therapies)
20. NCI Special Conference: Androgen Receptor in Prostate Cancer: Translating Biology into
Clinical Practice. Arlington, VA. December 6-7, 2010 (Models of Tumor Development (e.g.
cancer stem cells))
21. P53 Pathway is Involved in the Pathogenesis of Small Cell Carcinoma of the Prostate. The
second Innovative Minds in Prostate Cancer Today (IMPaCT) conference. Department of
Defense Prostate Cancer Research Program (PCRP). Orlando, FL, March 2011
22. Individualized treatment for cancer. Invited Speaker. Technical Symposium of 49th
anniversary of the Chinese-American Engineers and Scientists Association of Southern
California (CESASC). San Gabriel, CA, April 2011
23. Tissue recombination technology in the study of tumor initiation cells for prostate cancer.
Invited Speaker. Steering Committee Meeting, Intestinal Stem Cell Consortium (ISCC).
Stowers Institute, Kansas City, Missouri, May 2011
24. Diagnostic Usage of Immunohistochemistry in Genitourinary Pathology. 4th
Biannual MD
Anderson Cancer Center-Fudan University Pathology Conference. May 14-15, 2011.
Shanghai, China.
25. International session moderator, 18th
Annual Meeting of Chinese Urological Association,
October 28-30, 2011. Nanjing, China
26. Speaker for Cancer Committee, Zhejiang University-UCLA Joint Center for Research,
Hangzhou, China. November 4, 2011
27. Recent Progress in Prostate cancer, Continuing Medical Education Conference of Chinese
Urological Association, Huangshan, China, November 12, 2011
28. Panel Member, NCI-MMHCC Pathology Consensus Report Workshop, April 17-18, 2012,
New York, NY
29. Pathology of prostate cancer. 2012 Hangzhou International Pathology Symposium, Hangzhou,
China, April, 2012 30. Pathology of testicular tumors. 2012 Hangzhou International Pathology Symposium, Hangzhou,
China, April, 2012 31. Small cell carcinoma of the prostate: Molecular mechanisms of carcinogenesis. The 7th
Forum of Prostate Disease. Shanghai, China, June 2012.
32. International session moderator, 19th
Annual Meeting of Chinese Urological Association,
November, 2012. Guangzhou, China
33. Application of Immunohistochemistry The annual Hangzhou Symposium on the recent
development of molecular diagnosis and treatment of tumors. Hangzhou, China, April 19-21,
2013
34. Neuroendocrine Differentiation in Prostate Cancer, International forum on translational
medicine of Urology, Tianjin, China, April 26-28, 2013
35. Neuroendocrine Differentiation in Prostate Cancer, the 2nd
Annual PCF China Scientific
Symposium, Shanghai, China, May 2013
36. Neuroendocrine Differentiation in Prostate Cancer, Annual Urology Conference, the 2nd
Affiliated Hospital of Zhejiang University, Hangzhou, China, May 2013
37. Genitourinary Pathology Case discussion, 2nd
Huaxia Pathology Forum, Guilin, China, June
2013
38. Targeted biopsy of prostate cancer, The 7th
Annual Forum of Prostate Diseases, Shanghai,
China, July 27, 2013
39. Challenges in the Diagnosis of Small Cell Neuroendocrine Carcinoma, The 7th
Annual
Forum of Prostate Diseases, Shanghai, China, July 27, 2013
40. Pathology and Biology of Neuroendocrine Prostate Cancer, Pathology Workshop for t-NEPC
organized by Prostate Cancer Foundation. New York, NY. July 31, 2013
41. Prostate Cancer Stem Cells, Annual Jingmeng Stem Cell Conference, Beijing, China, Feb 15,
2014
42. Active surveillance for low grade prostate cancer. The Annual Meeting of the Basic Science
Division, Chinese urologic Association, April 26, 2014.
Presentations in conferences (platform and poster presentations)
1. Huang J, Wistuba I, Behrens C, Gazdar AF, Kornacki S and Jagirdar J. Utilization of
microdissection, PCR and LOH assay in the study of combined and collision tumors. 86th
Annual Meeting, United States and Canada Academy of Pathology, 1997; Orlando, Florida
2. Huang J, Melamed M. Dysplastic (“in-situ”) lesions in multifocal renal oncocytomas. 89th
Annual Meeting, United States and Canada Academy of Pathology, 1999; San Francisco,
California
3. Vargas R, Bourn P and Huang J. Immunostaining for Calponin can completement 34E12
in prostatic biopsy. 90th
Annual Meeting, United States and Canada Academy of Pathology,
2001; Atlanta, Georgia
4. Li R, Ni J, Yeh S, di Sant’agnese and Huang J. Cell block array: Development of a novel
technique for the study of cultured cells by immunohistochemistry. 92th
Annual Meeting,
United States and Canada Academy of Pathology, 2003; Washington, D.C.
5. Li R, di Sant’agnese and Huang J. Frequent expression of human carcinoma-associated
antigen (HCA), a mucin-type glycoprotein, by cells of prostatic carcinoma 92th
Annual
Meeting, United States and Canada Academy of Pathology, 2003; Washington, D.C.
6. H Li, L Zhang, I Ding, J Huang, PA diSant Agnese, H Lou, JY Lei. Over-Expression of
Decoy Receptor 3 in Precancerous Lesions and Adenocarcinoma of the Esophagus. Mod
Path. 2003. 17: S1; 121A. Presented at 94th
Annual Meeting of the United States and
Canadian Academy of Pathology, Vancouver, BC, March 2004.
7. S Liang, J Huang, PA Bourne, PA diSant Agnese, J Yao, JY Lei. Over-Expression of
Human Carcinoma-Associated Antigen in Precancerous Lesions and Adenocarcinoma of the
Esophagus. Mod Path. 2003. 17: S1; 121A-122A. Presented at 94th
Annual Meeting of the
United States and Canadian Academy of Pathology, Vancouver, BC, March 2004.
8. Yao JL, Alvarez VA, Bourne PA, Lei JY, di Sant’Agnese PA, and Huang J. Neuroendocrine
Cells Correlate with Proliferation Centers in Benign Nodular Prostatic Hyperplasia. Mod
Path. 2003. 17: S1; 185A. Presented at 94th
Annual Meeting of the United States and
Canadian Academy of Pathology, Vancouver, BC, and March 2004.
9. Yao JL, Li R, Bourne PA, Lei JY, di Sant’Agnese PA, and Huang J. Overexpression of
Human Carcinoma-Associated Antigen (HCA) in Urothelial Carcinoma of the Bladder. Mod
Path. 2003. 17: S1; 185A. Presented at 94th
Annual Meeting of the United States and
Canadian Academy of Pathology, Vancouver, BC, March 2004.
10. Yao JL, McClaskey JH, Quinn A, Bourne PA, Lei JY, di Sant Agnese PA and Huang J.
Mucin Expression in Benign and Neoplastic Prostate Using Tissue Microarrays. Mod Path.
2003. 17: S1; 185A-186-A. Presented at 94th
Annual Meeting of the United States and
Canadian Academy of Pathology, Vancouver, BC, March 2004.
11. JY Lei, PA Bourne, J Huang, PA diSant Agnese.Thyroid Transcription Factor-1 as a Useful
Marker in the Differential Diagnosis of Hepatocellular Carcinoma from Cholangiocarcinoma
and Metastatic Carcinoma in the Liver. Mod Path. 2003. 17: S1; 306A. Presented at 94th
Annual Meeting of the United States and Canadian Academy of Pathology, Vancouver, BC,
March 2004.
12. Huang J, Yao JL, Zhang L, Bourne PA, Quinn AM, di Sant’Agnese PA and Reeder JE.
Differential expression of Interleukin-8 and its receptors in the neuroendocrine and non-
neuroendocrine compartments of prostate cancer. 2005 AACR Annual Meeting, Anaheim,
California, April 2004 13. Yao JL, Bourne PA, Lei JY, Yang X, Tickoo SK, Liu Z, Huang J and Di Sant Agnese PA.
Expression of Novel Markers in Small Cell Carcinoma of the Prostate: Possible Therapeutic
Targets. Mod Path. 2005. 18: S1; 173A. 95th
Annual Meeting of the United States and
Canadian Academy of Pathology, San Antonio, TX, February 2005.
14. Nigwekar P, Yao JL, di Sant'Agnese PA, Mayer RD, Reeder JE, Huang J. Overexpression
of Heme Oxygenase-1 in Prostate Cancer. Presented at the 95th Annual Meeting of the
United States and Canadian Academy of Pathology, Atlanta, GA, February 2006.
15. Simon R, Bourne PA, di Sant’Agneses PA, Huang J and Yao JL. Mini Chromosome
Maintenance Protein 6 Expression in the Prostate: a Tissue Microarray Analysis. Presented at
the 95th Annual Meeting of the United States and Canadian Academy of Pathology, Atlanta,
GA, February 2006.
16. Golijanin DJ, Wood RW, Madeb RR, Silvers CR, Yao JL, Huang J, Messing EM, Reeder
JE, Joseph JV. Intraoperative Visualization of Cavernous Nerves Using Near Infrared
Fluorescence of Indocyanine Green in the Rat. Presented at the 101st Annual Meeting of the
American Urological Association, Atlanta, GA, May 2006.
17. Simon R, di Sant'Agnese PA, Yao JL, Bourne PA, Bohrer KA and Huang J. Prostate Cancer
is Associated with Increased Expression of Nuclear Cyclin D1. Accepted for presentation at
the 96th Annual Meeting of the United States and Canadian Academy of Pathology, San
Diego, CA, March 2007.
18. Li L, Simon R, Spauldin BO, Bourne PA, Yao JL, di Sant'Agnese PA, Xu H and Huang J.
KOC is a Useful Marker for the Classification of Urothelial Neoplasms of the Bladder.
Accepted for presentation at the 96th Annual Meeting of the United States and Canadian
Academy of Pathology, San Diego, CA, March 2007.
19. Li L, Bourne PA, Yao JL, di Sant'Agnese PA, Zhuang Z, Yin C, Wu C and Huang J.
Myosin VI, a Mediator of The P53-Dependent Cell Survival Pathway, is Overexpressed in
Adenocarcinoma of the Prostate. Accepted for presentation at the 96th Annual Meeting of the
United States and Canadian Academy of Pathology, San Diego, CA, March 2007.
20. Lester TR, Kohli M, Quinn A, Reeder JE, Yao JL, di Sant'Agnese PA, Bourne PA and
Huang J. Expression of Thrombin in the Prostate: Implications for Carcinogenesis and
Tumor-associated Hypercoagulation. Accepted for presentation at the 96th Annual Meeting
of the United States and Canadian Academy of Pathology, San Diego, CA, March 2007.
21. Nigwekar P, Lester TR, Yang Q, Bourne PA, Yao JL, di Sant'Agnese PA, Zhai J, Wang H
and Huang J. Overexpression of Human Carcinoma-Associated Antigen (HCA) in
Pancreatic Adenocarcinoma. Accepted for presentation at the 96th Annual Meeting of the
United States and Canadian Academy of Pathology, San Diego, CA, March 2007.
22. Nigwekar P, Wu C, Yao JL, Bourne PA, Li J, Zhuang Z, di Sant'Agnese PA, Walters DC
and Huang J. Nucleophosmin, a Critical Regulator of Cell Proliferation, is Overexpressed in
Prostate Cancer. Accepted for presentation at the 96th Annual Meeting of the United States
and Canadian Academy of Pathology, San Diego, CA, March 2007.
23. Simon RA, Xu H, Bourne PA, Yao JL, Wei J, Liang S, Liu, J, di Sant'Agnese PA, Cheng L,
and Huang J. CD44 is a Useful Marker for Prostatic Small Cell Carcinoma. 97th Annual
Meeting, United States and Canada Academy of Pathology, Denver, CO 2008
24. Wagner DG, Scott G,Yang Q and Huang J. Stem Cell-Associated Markers Are Useful in
Distinguishing Melanoma From Nevi. 98th Annual Meeting, United States and Canada
Academy of Pathology, Boston, MA 2009
25. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang
L-S, Yang Q and Huang J. Selective expression of CD44, a putative prostate cancer stem
cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate Cancer
Foundation Scientific Retreat. Reno, NV, Sept 2009
26. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang
L-S, Yang Q and Huang J. Selective expression of CD44, a putative prostate cancer stem
cell marker, in neuroendocrine tumor cells of human prostate cancer. NCI Translational
Science Meeting, Tyson Corer, VA. Nov 2009
27. Mulholland DJ, Kobayashi N, Johnston M, Sun Z, Morim A, Wu L, Huang J, Wu H.
Cooperativity between Pten loss and K-ras activation in promoting EMT and metastasis in
murine prostate cancer. AACR Special Conference (EMT and Cancer Progression and
Treatment) Arlington, Virginia, 2010
28. Clebanoff JL, Magyar C, Yao JL, di Sant'Agnese PA, Cheng L, Yang Q, Li X and Huang J.
p53 Pathway is Involved in the Pathogenesis of Small Cell Carcinoma of the Prostate. 99th
Annual Meeting, United States and Canada Academy of Pathology, Washington DC, 2010
29. Wagner D, Miller E, Yang Q, Scott G, Rubin BP and Huang J. Stem Cell-Associated
Markers Distinguish Melanoma from Malignant Peripheral Nerve Sheath Tumor. 99th
Annual
Meeting, United States and Canada Academy of Pathology, Washington DC, 2010
30. Huss J, Raman S and Huang J. Kidney Biopsy for Tumors: Pathologic Interpretation and
Clinical Significance. 100th
Annual Meeting, United States and Canada Academy of
Pathology, San Antonio, TX 2011
31. Miller E, Rettig M, Magyar C and Huang J. Strong and Diffuse Nuclear Staining for
Phospho-c-Jun Distinguishes Clear Cell Renal Cell Carcinoma from its Mimickers. 100th
Annual Meeting, United States and Canada Academy of Pathology, San Antonio, TX 2011
32. Palla B, Zhang H and Huang J. A Novel Method to Procure Fresh Prostate Tissue for Viable
Epithelial Cells. 100th
Annual Meeting, United States and Canada Academy of Pathology,
San Antonio, TX 2011
33. Marks L, Natarajan S, Margolis D, Huang J, Kumar D, Narayanan R, Bentley R, Macairan
ML and Lieu P. Artemis: An Office-Based Device For MRI Fusion And Targeted Prostate
Biopsy. American Urologic Association Annual Meeting, Washington DC, May 2011
34. Song G, Natarajan S, Margolis D, Huang J, Dorey F, Macairan ML, Lieu P and Marks LS.
Value of Targeted Biopsy in Detecting Prostate Cancer using an Office-Based MR-US
Fusion Device. American Urologic Association Annual Meeting, Atlanta, GA, May 2012
35. Gollapudi K, Galet C, Grogan T, Zhang H, Huang J, Elashoff D, Gerber L, Freedland S,
Rettig M, Aronson W. Is infiltration of tumor-associated macrophages predictive of
biochemical recurrence after radical prostatectomy? American Urological Association
Annual Meeting, Atlanta, GA May 20, 2012
36. Susan Kerkoutian, Yin Sun, Xinmin Li, Jason Scapa, Jiaoti Huang. Cell Type-Specific
Biomarkers to Predict the Risk of Prostate Cancer in Men with Increased PSA but Negative
Biopsies. United States and Canadian Academy of Pathology Annual Meeting, March 2013,
Baltimore, MD
37. Karow D., White N., Huang J., Reiter R., Mattrey R., Margolis D., Raman S., Dale A.
Improved Conspicuity and Delineation of High-Grade Prostate Tumors Using “Restriction
Spectrum Imaging”: Quantitative Comparison with High B-Value ADC. The International
Society for Magnetic Resonance in Medicine 21st Annual Meeting & Exhibition, 20-26
April 2013, Salt Lake City, Utah, USA
38. Geoffrey Sonn, Shyam Natarajan, Daniel Margolis, Edward Chang, Malu Macairan, Patricia
Lieu, Jiaoti Huang, Frederick Dorey, Leonard Marks. Prospective Evaluation of MRI-
Ultrasound Fusion Biopsy to Diagnose Prostate Cancer in Men with Prior Negative Biopsies.
American Urological Society Annual Meeting, May 2013, San Diego, CA
39. Geoffrey Sonn, Shyam Natarajan, Daniel Margolis, Edward Chang, Malu Macairan, Patricia
Lieu, Jiaoti Huang, Frederick Dorey, Leonard Marks. Targeted Biopsy with MRI-Ultrasound
Fusion. American Urological Society Annual Meeting, May 2013, San Diego, CA
40. Nils Kroeger, David B. Seligson, Sabina Signoretti, Hong Yu, Frederic D. Birkhaeuser, Clara
Magyar, Jiaoti Huang, Joseph Riss, Fairooz F. Kabbinavar, Arie S. Belldegrun, Allan J.
Pantuck. Investigating the association of cytoplasmic and nuclear HIF-2 expression with
cancer specific survival (CSS) in clear cell renal cell carcinoma. American Society of
Clinical Oncology Genitourinary Cancers Symposium, February 2013, Orlando, FL
41. Mitchell Kamrava, Shane Mesko, Robyn Banerjee, Jiaoti Huang, D. Jeffrey Demanes,
Leonard S. Marks. Quantifying the ki-67 heterogeneity profile in prostate cancer. American
Society of Clinical Oncology Genitourinary Cancers Symposium, February 2013, Orlando,
FL
42. Lindsay Ann Schelling; Sean Williamson; Jorge Yao; Shaobo Zhang; Mingsheng Wang;
Huang, Jiaoti; Antonio Lopez; Adeboye Osunkoya; Gregory MacLennan. ERG
Immunohistochemistry in Prostatic Small Cell Carcinoma: Comparison to Fluorescence in
situ Hybridization. United States and Canadian Academy of Pathology Annual Meeting,
March 2013, Baltimore, MD
43. Geoffrey Sonn MD, Edward Chang, Shyam Natarajan, Frederick Dorey, Daniel Margolis ,
Jiaoti Huang, Patricia Lieu, Malu Macairan and Leonard Marks. Impact of MR-Us Fusion
Targeted Confirmatory Biopsy on Patient Selection for Active Surveillance. Society for
Urologic Oncology Annual Meeting, May 2012, Atlanta, GA
44. Boon-Unge K, Yi J, Huang J, Yong WH, Vinters HV, De Jesus J, Vehabedian N, Khanlou N.
Combined Brachyury/CA-IX immunohistochemistry in the diagnosis of notochordal tumors
with atypical features. 89th annual meeting of the American Association of
Neuropathologists. J Neuropathol Exp Neurol. 2013;72(6):540-598.
45. D Margolis, S Raman, E Chang, F Dorey, J Huang, P Lieu, M Macairan, S Natarajan, R
Reiter, G Sonn, L Marks. Detection Rate for Prostate Cancer Using MRI-Ultrasound Fusion
in a Biopsy-Naïve Population. Radiological Society of North America Scientific Assembly
and Annual Meeting, Chicago IL, 1-6 December 2013
46. Mo Z. and Huang J. Expression of androgen receptor splicing variant in benign prostate,
prostatic adenocarcinoma and small cell neuroendocrine carcinoma. United States and
Canada Academy of Pathology annual meeting. San Diego, CA, March 2014
